FDA advisory committees recommend approval of ultra rapid-acting mealtime insulin therapy
VALENCIA, Calif. — MannKind Corp. on Tuesday announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the Food and Drug Administration voted 13-to-1 to recommend that Afrezza (insulin human [rDNA origin]) inhalation powder be granted marketing approval by the FDA to improve glycemic control in adults with Type 1 diabetes and voted 14-to-0 to recommend that Afrezza be granted marketing approval by the FDA to improve glycemic control in adults with Type 2 diabetes.
If approved, AFREZZA would be the first ultra rapid-acting mealtime insulin therapy available in the United States.
"We are pleased with the Advisory Committee’s approval recommendation in support of Afrezza, and we appreciate the thoroughness of their review," stated Alfred Mann, chairman and CEO MannKind Corporation. "We look forward to working with the FDA as they complete their evaluation of Afrezza."
McKesson recognized for McKesson OneCloud technology solution
SAN FRANCISCO — McKesson on Thursday announced that it ranked No. 8 on this year’s InformationWeek Elite 100.
McKesson was recognized for its development of McKesson OneCloud, an internally developed private and public cloud capability used in the development of internal and customer-facing solutions. OneCloud enables McKesson technologists to meet the demands for secure, regulated exchange of healthcare information, while providing the organization with low-cost agile development environments. Taking advantage of economies of scale with OneCloud, the organization can more easily leverage newer technologies to drive business growth, lower costs and reduce development time to more quickly bring solutions to market.
“McKesson is honored to be recognized as one of today’s top technology innovators,” stated Randy Spratt, chief information officer and chief technology officer, McKesson. “As a leader in healthcare, McKesson is committed to evolving our business through the innovative use of technology to shape the future of healthcare and to help our customers and their patients achieve better health.”
OneCloud is a self-service business model serving as the platform for the next generation of McKesson’s products and services. With OneCloud, McKesson business and technology workers can provision new cloud servers or business applications in just minutes. The project speeds up the delivery of business and technology apps used by McKesson’s business units, who in turn serve the company’s external customers, without compromising on security or technology standards.
Walgreens posts March sales of $6.4 billion, up 4.5%
DEERFIELD, Ill. — Walgreens on Thursday reported March sales of $6.4 billion, an increase of 4.5% as compared with the same month in fiscal 2013.
With Easter falling on April 20 this year compared with March 31 last year, total front-end sales decreased 2.6% in March compared with the same month in fiscal 2013, while comparable store front-end sales decreased 3.4%. Customer traffic in comparable stores decreased 4% while basket size increased 0.6%. Walgreens will report combined comparable store sales for March and April with its April sales results.
Prescriptions filled at comparable stores increased by 5.1% in March and increased 4.2% on a calendar day-shift adjusted basis. March 2014 had one additional Monday and one fewer Friday compared with March 2013. These calendar shifts positively impacted prescriptions filled at comparable stores by 90 basis points. Prescriptions filled at comparable stores were negatively impacted by 30 basis points due to the lower incidence of flu in March 2014.
March pharmacy sales increased by 8.9%. Comparable store pharmacy sales increased 8% and increased by a calendar day-shift adjusted 7.1%. Calendar day-shift adjusted comparable store pharmacy sales were negatively impacted by 160 basis points due to generic drug introductions in the last 12 months, and were negatively impacted by 40 basis points due to a lower incidence of flu.
Pharmacy sales accounted for 64.7% of total sales for the month.
Sales in comparable stores increased by 3.5% in March. Calendar day shifts positively impacted total comparable sales by 0.6%. Generic drug introductions in the last 12 months negatively impacted total comparable sales by 100 basis points, while the lower incidence of flu negatively impacted total comparable sales by 20 basis points.
Fiscal 2014 year-to-date sales for the first seven months were $44.4 billion, an increase of 5.4%.
Walgreens opened 13 stores during March, including three relocations, acquired three and closed one.